1. Home
  2. RVNC vs IKT Comparison

RVNC vs IKT Comparison

Compare RVNC & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVNC
  • IKT
  • Stock Information
  • Founded
  • RVNC 1999
  • IKT 2008
  • Country
  • RVNC United States
  • IKT United States
  • Employees
  • RVNC N/A
  • IKT N/A
  • Industry
  • RVNC Biotechnology: Pharmaceutical Preparations
  • IKT Biotechnology: Pharmaceutical Preparations
  • Sector
  • RVNC Health Care
  • IKT Health Care
  • Exchange
  • RVNC Nasdaq
  • IKT Nasdaq
  • Market Cap
  • RVNC 546.4M
  • IKT N/A
  • IPO Year
  • RVNC 2014
  • IKT 2020
  • Fundamental
  • Price
  • RVNC $5.20
  • IKT $1.71
  • Analyst Decision
  • RVNC Buy
  • IKT Strong Buy
  • Analyst Count
  • RVNC 10
  • IKT 1
  • Target Price
  • RVNC $10.86
  • IKT $5.00
  • AVG Volume (30 Days)
  • RVNC 2.3M
  • IKT 1.1M
  • Earning Date
  • RVNC 11-06-2024
  • IKT 11-12-2024
  • Dividend Yield
  • RVNC N/A
  • IKT N/A
  • EPS Growth
  • RVNC N/A
  • IKT N/A
  • EPS
  • RVNC N/A
  • IKT N/A
  • Revenue
  • RVNC $251,178,000.00
  • IKT $79,570.00
  • Revenue This Year
  • RVNC $20.36
  • IKT N/A
  • Revenue Next Year
  • RVNC $31.66
  • IKT N/A
  • P/E Ratio
  • RVNC N/A
  • IKT N/A
  • Revenue Growth
  • RVNC 40.23
  • IKT N/A
  • 52 Week Low
  • RVNC $2.30
  • IKT $0.80
  • 52 Week High
  • RVNC $9.90
  • IKT $3.82
  • Technical
  • Relative Strength Index (RSI)
  • RVNC 38.45
  • IKT 75.16
  • Support Level
  • RVNC $5.08
  • IKT $1.15
  • Resistance Level
  • RVNC $5.41
  • IKT $1.88
  • Average True Range (ATR)
  • RVNC 0.19
  • IKT 0.17
  • MACD
  • RVNC -0.01
  • IKT 0.06
  • Stochastic Oscillator
  • RVNC 38.00
  • IKT 77.33

About RVNC Revance Therapeutics Inc.

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Share on Social Networks: